Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00125
|
|||||
Drug Name |
Levodopa
|
|||||
Synonyms |
Levodopa (optimized formulation, Parkinson's disease); Levodopa (optimized formulation, Parkinson's disease), Orion; More effective levodopa (Parkinson's disease), Orion
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Parkinson's Disease [ICD11: 8A00.0] | Approved | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C9H11NO4
|
|||||
Canonical SMILES |
C1=CC(=C(C=C1CC(C(=O)O)N)O)O
|
|||||
InChI |
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
|
|||||
InChIKey |
WTDRDQBEARUVNC-LURJTMIESA-N
|
|||||
CAS Number |
CAS 59-92-7
|
|||||
Pharmaceutical Properties | Molecular Weight | 197.19 | Topological Polar Surface Area | 104 | ||
Heavy Atom Count | 14 | Rotatable Bond Count | 3 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
-2.7
|
|||||
PubChem CID | ||||||
PubChem SID |
10321285
, 11111115
, 11112155
, 11335627
, 11360866
, 11363348
, 11365910
, 11368472
, 11374316
, 11376634
, 11461838
, 11466045
, 11467165
, 11484127
, 11485710
, 11488312
, 11492354
, 11494268
, 11532916
, 11537951
, 15120911
, 15219946
, 17405017
, 222573
, 24277914
, 24863554
, 26613179
, 26679497
, 26719283
, 26746620
, 26753566
, 29225059
, 3136680
, 3648
, 46508120
, 47216726
, 47291084
, 47440197
, 47440198
, 47736420
, 47810699
, 47959681
, 555833
, 7847127
, 7886892
, 7979689
, 8001566
, 8143351
, 8150164
, 8153771
|
|||||
ChEBI ID |
ChEBI:15765
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | LAT1 | Transporter Info | L-type amino acid transporter 1 | Substrate | [2] | |
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | LAT1 | Transporter Info | Km = 200 microM | Human embryonic kidney cells (HEK293)-LAT1 | [2] | |
References | ||||||
1 | Levodopa was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017 Mar 8;7:43580. | |||||
3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.